MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL AFTER >3 YEARS OF FOLLOW-UP: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY